ASH 2016: Hemato-oncologie Journaal 3

December 15, 2016

  • Deel deze pagina:

Samen met dr. Annemiek Broijl uit het Erasmus MC in Rotterdam bespreken we het meest interessante nieuws op het gebied van multipel myeloom. We sluiten de hemato-oncologie Journaals af met een samenvatting van de late-breaking sessie door Selina Luger, MD, uit het Hospital of the University of Pennsylvania in Philadelphia.

Presentatie: Inge Diepman



  • 242 Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)SCT vs ponatinib
  • 991 Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Lenalidomide onderhoudstherapie

  • 1143 Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Venetoclax bij RR pten

  • 488 Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Nelfinavir bij proteasome-inhibitor resistentie

  • 487 The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Late-breaking spreker: Selina Luger MD, University of Pennsylvania Philadelphia

  • LBA-1 Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial)
  • LBA-5 Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl
  • LBA-6 Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1

Studietuin: drs. Ruth Wester

  • 1141 Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Dit programma wordt financieel mogelijk gemaakt door Novartis, BMS en Janssen.

Gerelateerde artikelen